Compare Lowe`s Companies Inc (LOW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Sanofi SA — how do they compare? Lowe`s Companies Inc trades at $214.21 (market cap $124.06B), while Sanofi SA trades at $43.47 (market cap $104.30B). The key difference: Lowe`s Companies Inc is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| LOW | SNY | |
|---|---|---|
Market Cap | $124.06B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $52.34 |
52-Week Low | $201.92 | $41.33 |
Enterprise Value | $165.81B | $124.19B |
Dividend Yield | 2.26% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $218.84, down 2.02% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company has beaten earnings estimates for the last three quarters, with Q2 2026 results expected on August 19. Revenue declined to $83.67 billion in 2025, but net income margin remained healthy at 7.51%. A $1.25 dividend is scheduled for payment on August 5, 2026.
The outlook is supported by strong analyst consensus, with a $257.06 price target implying 17% upside. Risks include high debt levels and competitive pressures. Earnings growth in the professional segment is a key catalyst, but macroeconomic headwinds could challenge DIY sales momentum.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
